Geriatric psychiatry returns. We tackle sleep problems and behavioral disturbances in patients with dementia with returning guest, and Geriatric Psychiatrist Dennis Popeo MD, Clinical Associate Professor of Psychiatry at NYU Langone Medical Center. Topics include: pharmacologic and nonpharmacologic management of insomnia; treating agitation and irritability; medical management of psychotic symptoms and paranoia; ethical concerns about the treatment of challenging behaviors in dementia; and the shortage of geriatricians and geriatric psychiatrists.
Written & Produced by: Jordana Kozupsky NP
Artwork by: Kate Grant MD
Hosts: Jordana Kozupsky NP, Matthew Watto MD
Editor: Matthew Watto MD
Guest: Dennis Popeo, MD
Ask your older adults patients and their family members about nocturia, and sleep wake reversal, which are common barriers to sleep. In fact, some big cities like New York have nocturnal adult daycare programs.
Make sure your patients are practicing basic sleep hygiene. These include the avoidance of liquids, cigarettes, and caffeine close to bedtime. Discourage patients from taking naps longer than 30 minutes. Dr. Popeo reminds us to manage expectations, “An 85 year old will not sleep for eight hours per night” (Review by Lavoie. BMC. 2017)
Check out this previous episode on Insomnia with Psychiatrist, Dr. Karl Doghramji from Thomas Jefferson University.
Dr. Popeo does not recommend the use of zolpidem and friends in older adults. They might work, but their long-term use makes symptoms of dementia worse (Cheng. J Am Geriatr Soc. 2017 PMID: 28884784 ) and they increase fall risk (Kolla. J Hosp Med. 2013).
Trazodone is an “older antidepressant” that is non habit forming. It has the beneficial side effect of sedation and doesn’t affect blood pressure like some other sleep aids. It can be helpful for sleep at doses of 25 to 50 mg at bedtime (Jaffer. Innov Clin Neurosci. 2017. PMC 5842888). Priapism is a rare complication. -Dr Popeo’s expert opinion
Gabapentin is sometimes used off-label and has some evidence for treatment of insomnia (Rosenberg. J Clin Sleep Med. 2014 PMID 25317090). Dr. Popeo suggests doses of 100 to 300 mg at bedtime might be helpful (expert opinion).
Mirtazapine has been helpful for sleep in geriatric patients with depression (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907331/). It should be noted that lower doses of mirtazapine (15 mg or less) are more sedating than higher doses. This may be due to more noradrenergic activation at higher doses (Hirsch et al. Atypical antidepressants: Pharmacology, administration, and side effects. UpToDate.com).
Melatonin is not helpful as a sleep aid in Dr. Popeo’s experience. Additionally, experts cannot seem to agree on dosing.
Dr. Popeo reminds listeners that they SHOULD NOT use diphenhydramine! Recall our previous episode on dementia where Dr. Steven Dekosky noted that anticholinergic medications blunt cognition in patients with dementia.
Irritability (or agitation) is a common symptom in dementia and should be considered separately from psychotic features like paranoia.
The mainstay of treatment for the neuropsychiatric symptoms remains nonpharmacologic strategies. Dr. Popeo advocates for cautious use of medical therapy when the potential benefits outweigh the risks of harm. Please refer back to our GeriSiders episode #82 with Eric Widera MD for a more in-depth discussion of this clinical conundrum.
Dr. Popeo notes that benzodiazepines are risky because they can be habit forming, even in older folks [Juergens. Mayo Clinic Proceedings 1993 ]. They increase the risk of falls, hip fractures and death [Donnelly. PLoS One. 2017]. They also may worsen cognition [Rochon. CMAJ. 2017], and there’s observational studies that link use to Alzheimer’s disease [Billioti de Gage. BMJ 2014], but there is not yet consensus about their long term effects on cognition. There is a low incidence of benzodiazepine induced respiratory depression because of low density of binding sites in the brainstem respiratory center [Kang. StatPearls. 2018 NBK 482238]. Respiratory depression is mostly a risk if mixed with alcohol or other substances (Dr. Popeo).
Dr. Popeo points out that, benzodiazepines are like alcohol. A small dose may cause disinhibition and the patient might act like a person at a party after a few glasses of wine. Therefore, it’s important to give enough that the person goes to sleep from the dose.
Dr. Popeo notes that the Black Box Warning [Steinberg. Am J Psychiatry. 2012] for both atypical and conventional antipsychotics probably overstates the risk, but it will never be removed. These agents may be considered for patients with dementia who express severe agitation or irritability, but this requires a complex risk/benefit analysis and discussion with the patient’s family members. That being said, the decision to use these agents is more straightforward if a patient has psychosis and/or paranoia. Patient’s with this type of symptoms warrant referral to a geriatric psychiatrist (Dr. Popeo’s expert opinion).
The CATIE-AD study, referenced by Dr. Popeo, tested the use of risperidone, olanzapine and quetiapine “on psychiatric and behavioral symptoms in patients with Alzheimer’s disease (AD) and psychosis or agitated behavior” (Sultzer. Am J Psychiatry. 2008). Risperidone and olanzapine showed some benefit for various psychiatric or behavioral symptoms versus placebo, but did not improve functional skills.
Dr. Popeo notes that risperidone comes in a liquid that is odorless, colorless, and tasteless. It can easily be mixed into patient’s food or drink for convenient dosing. He reminds us that the goal is to keep the patient in their home in a safe way, and uncontrolled behavioral symptoms are a barrier to this goal.
Citalopram at 30 mg per day significantly reduced caregiver stress and agitation in patients with Alzheimer’s disease (Porsteinsson. JAMA. 2014), but it’s use is limited by cognitive side effects and cardiac toxicity (prolonged QTc) at doses over 20 mg per day.
Gabapentin has been effective for nocturnal agitation in at least one case report (Buskova. Med Sci Monit. 2011).
Trazodone may help with agitation and psychosis in dementia, but further studies are needed [Seitz. Cochrane Database Syst Rev. 2011]
Caregiver stress is a major factor that leads to nursing home placement. Therefore, it must be addressed if you want to keep people in their homes. -Dr Popeo
Behavioral interventions work well in studies, but not as well for families in real world settings. For this reason, pharmacologic interventions are often pursued.
There is a “Dementia Village” set up at a nursing home in the small town of Weesp, in Holland (Gizmodo article by Campbell-Dollaghan). Unfortunately, this option is not widely available or practical at this time.
There is about one geriatric psychiatrist for every 8,000 to 9,000 people so primary care clinicians must be proficient in managing these issues. –Dr Popeo
Listeners will develop an approach to the pharmacologic and nonpharmacologic management of sleep and behavioral disturbances in older adults with dementia.
After listening to this episode listeners will…
Dr. Popeo and The Curbsiders report no relevant financial disclosures.
Two papers by Dr. Popeo and friends on Geriatric Psychiatry
The Curbsiders are partnering with VCU Health Continuing Education to offer FREE continuing education credits for physicians and other healthcare professionals. Visit curbsiders.vcuhealth.org and search for this episode to claim credit.
Got feedback? Suggest a Curbsiders topic. Recommend a guest. Tell us what you think.
We love hearing from you.
Yes, you can now join our exclusive community of core faculty at Kashlak Memorial Hospital along with all the perks:
Notice
We and selected third parties use cookies or similar technologies for technical purposes and, with your consent, for other purposes as specified in the cookie policy. Denying consent may make related features unavailable.
Close this notice to consent.